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Abstract
Background: This crossover, randomized, double-blind study (conducted over a 32-week period) was performed to
determine, in clinically stable Cystic fibrosis (CF) preschool children: the effects of 7% inhaled hypertonic saline on
spirometry and interrupter resistance technique (Rint), and the possible side effects.
Methods: Twelve CF children (6M, mean age ± SD: 5.7 ± 0.8 yrs) were enrolled and randomly assigned to receive
hypertonic saline (HS-4 ml 7% sodium chloride), or normal saline (NS-0.9% sodium chloride) twice a day. After a
16 weeks period, therapy was exchanged to allow all the patients enrolled in the study to carry out both treatments.
Monitoring visits, spirometry (COSMED Quark PFT4 ergo) and Rint were scheduled at 0,4,16,20,32 weeks. At T0, spirometric
measurements and Rint were performed immediately before and 30 min after the inhalation therapy. Salbutamol
(400 mcg) was administered before the drug at each visit.
Results: After a 16-weeks treatment with HS an improvement of FVC (p = 0.02) and a favorable trend of FEV1 were
registered. A worsening of FEV1 (p < 0.0001) and of FEF25-75 (p = 0.019) were found in NS group. No differences were
found in expiratory and inspiratory Rint in both groups. No serious adverse events occurred.
Conclusions: Seven percent hypertonic saline therapy proved to be a useful and safe treatment in young CF children
with clinically stable conditions.
Trial registration: ISRCTN12345678.
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Background
Cystic fibrosis (CF) is the most common hereditary disease
in Caucasians. It is caused by mutations in the CF trans-
membrane conductance regulator (CFTR) chloride chan-
nel. This mutations lead to an abnormal ion transport
across the respiratory epithelium with a defective chloride
secretion and excessive sodium absorption that finally
cause dehydration of the airway surface liquid. The
disruption of mucociliary clearance, apparently closely
dependent on the presence of an inadequate volume of
airway surface liquid, plays a basic role in the vicious cycle
of airway obstruction, infection, inflammation and lung
damage [1]. According to this hypothesis, inhaled hyper-
tonic saline (HS) represents a well-documented therapy in
adults [1, 2], as the already established but very expensive
treatment with rhDNase [2, 3].
The effects of the HS on pulmonary function tests have
been assessed in young children with CF [4–6], providing
to be associated with an improvement in lung function
and marked benefits with respect to exacerbations [7].
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This crossover, randomized double-blind study was
designed to determine as primary outcomes, in pre-
school children with CF: the effects of an inhaled hyper-
tonic solution on spirometry (measured as follows:
forced volume vital capacity – FVC, forced expiratory
volume in 1 s - FEV1 and forced expiratory flow 25–
75% - FEF25-75) and airways resistance assessed by The
Interrupter technique (Rint). As secondary outcome the
possible side effects of the treatment were evaluated.
Methods
Study population
Over the period September 2012 - September 2013, chil-
dren with a confirmed diagnosis of cystic fibrosis by
sweat test and genetic analysis, were enrolled.
Eligible subject included clinically stable preschool
children with CF undergoing a simple therapy based on
bronchodilator (salbutamol) and physiotherapy. Children
were considered stable whether: FEV1, measured at
screening, was at least 70% of predicted value for height,
weight, age and sex, as well as the expiratory resistance
was lower than 150% of predicted values [8]. Moreover,
they should not be colonized with Burkholderia Cepacia,
or have respiratory infections during the treatment or
2 weeks before and therapy with rhDNase or routinely
use of antibiotics.
Study design
A crossover, double-blind randomized study was con-
ducted over a 32-week period (Fig. 1). Randomization
was performed using a randomization table. Patients
were enrolled and assigned blindly to one of the group by
the attending physician. Children were randomly assigned
to receive a 4 ml treatment with hypertonic saline (HS –
7% sodium chloride), or normal saline (NS - 0.9% sodium
chloride) twice daily. A bronchodilator (400 mcg of salbu-
tamol) was administered 20 min before each inhalation of
the study solution. After a 16 weeks period, therapy was
exchanged to allow all the patients enrolled in the study to
carry out both treatments.
Monitoring visits were scheduled at 0, 4, 16, 20,
32 weeks. At each visit, participants underwent history
and physical examination, sputum collection with its
microbiological examination and susceptibility testing,
baseline spirometry and measurement of airway resist-
ance by Rint.
Pulmonary function testing was performed with the
COSMED Rocc Quark PFT4 ergo (Rome,Italy) device at
the Cystic Fibrosis Centre, of the Pediatric Department,
“Sapienza” University of Rome.
Lung function test
Airway resistance was measured using the interrupter
resistance technique (Rint). Each single interruption was
considered acceptable when the trace of mouth pressure
versus time showed the correct shape [9]. The Rint
measurement was taken with the child sitting comfortably
and voluntarily, during quiet spontaneous respiration,
using a disposable mouthpiece with an antibacterial filter
device. The child was instructed to put the nasal clip in
place, closing the lips around the mouthpiece and placing
the tongue under the mouthpiece. The researcher sup-
ported the face and chin of the child in order to avoid
energy loss and reduce the effect of upper airway compli-
ance. The head was held in neutral position. Researchers
trained in the method performed the measurements [10].
At each visit, a bronchodilator (400 mcg of salbutamol)
was administered via a metered dose inhaler and large vol-
ume spacer (Volumatic, Glaxo, UK) 20 min before the in-
haled HS or NS administered using a pediatric aerosol
nebulizer (OS80/P) aerosol therapy mask. Rint was per-
formed before spirometry, as the deep inspiration pre-
ceding the forced expiratory maneuver required to
perform spirometry could influence the bronchial tone.
Fig. 1 Study design: weeks and visits in the two groups of children
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Spirometric measurements and Rint were performed
immediately before the bronchodilator at the start of
study. Spirometry measures were reported as absolute
values and % predicted values, according to the global
lung initiative reference data [11]. Rint measurements
were taken according to the ATS/ERS recommendation
[8]. Another spirometry and Rint were performed
30 min after the inhalation therapy (HS or NS) at T0,
T4 and T16. Values obtained after the administration of
the bronchodilator at T0 were used for starting values.
Statistical analysis
All statistical calculations were performed using SPSS
for Windows version 21.0 (SPSS, Inc., Chicago, Illinois,
USA). A paired sample t-test was used to evaluate dif-
ference between mean values for each treatment at
time 0 (T0), at 4 (T4) and 16 weeks (T16). Results
were expressed as mean ± SD. Significance levels were
set at ≤0.05.
All parents of children gave written informed consent
and the protocol (prot. HS-2009) was approved by the
Scientific Ethics Committee, Policlinico Umberto I.
Results
Insofar as 1 child had respiratory infections, he was ex-
cluded. A total of 12 children (six males, mean age ± SD:
5.7 ± 0.8 years) with a confirmed diagnosis of cystic fi-
brosis were enrolled (Table 1).
All the 12 patients completed the entire protocol. At
T0 no differences were found in terms of mean FVC,
FEV1 and FEF25-75 as well as mean expiratory and in-
spiratory Rint between HS and NS groups. The spu-
tum following administration of HS were almost
unchanged during the study protocol (not colonization
with Burkholderia Cepacia nor new respiratory infec-
tions). We did not record any exacerbations of respira-
tory infections in both groups.
At T0 after bronchodilator, significant improvements
of FVC, FEV1 and FEF25-75 were found in both groups
(HS: FVC: 1.36 ± 0.4vs1.42 ± 0.4 L, p = 0.008; FEV1:
1.08 ± 0.2vs1.25 ± 0.4 L, p = 0.045; FEF25-75:
1.31 ± 0.3vs1.43 ± 0.2 L/s, p = 0.009. NS: FVC:
1.23 ± 0.3vs1.31 ± 0.4 L, ns; FEV1: 1.09 ± 0.3vs1.25 ± 0.2 L,
p = 0.001; FEF25-75: 1.35 ± 0.3vs1.51 ± 0.4 L/s,
p = 0.027). Significant Rint reductions were also mea-
sured (HS: Rint exp.: 1.51 ± 0.2vs1.25 ± 0.2 KPa,
p < 0.0001; Rint insp.: 1.40 ± 0.2vs1.26 ± 0.2 KPa,
p = 0.018. NS: Rint exp.: 1.49 ± 0.4vs1.23 ± 0.2 KPa,
p = 0.029; Rint insp.:
1.35 ± 0.2vs1.19 ± 0.2 KPa, p = 0.001).
After a 4-weeks treatment with HS, as compared to
baseline values, only an improvement of %predicted
FVC (p = 0.048) was found (Table 2). Worsening of
%predicted FVC (p = 0.01), FEV1 (p < 0.0001), %pre-
dicted FEV1 (p < 0.0001), %predicted FEF25-75
(p = 0.001), FEF25-75 (p = 0.012) and expiratory Rint
(p = 0.02) was detected in NS groups (Table 3).
After a 16-weeks treatment with HS, as compared to
baseline values, an improvement of FVC (p = 0.02) and
%predicted FVC (p = 0.02) was found. A favorable trend
of FEV1 was registered, although it failed to reach statis-
tical significance. The mean values of expiratory and in-
spiratory resistance remained substantially unchanged
(Table 2). On the contrary, a significant worsening of
FEV1 (p < 0.0001) and FEF25-75 (p = 0.019) were found
after the treatment with normal saline (Table 3).
The mean FVC, FEV1 and FEF25-75 improvements
as well as expiratory and inspiratory Rint reductions,
between T0 and T16 were higher in HS than in NS
group, however, these were not-significant (data not
shown).
Figure 2 graphically represents the mean absolute dif-
ference in FVC, FEV1, FEF25-75 and expiratory and in-
spiratory Rint from the baseline at T0, T4 and T16 for
the two treatment groups. Inspection of the data showed
that spirometric and Rint parameters appeared to con-
stantly improve at T0 and T16 in HS group but
remained essentially unchanged at T4 and slightly im-
proved at T16 in NS group.
No serious adverse events occurred in both groups. In
the HS group, cough was observed (two patients) and,
generally, disappeared after the first administration of
HS, while one child complained about the unpleasant
taste.
Discussion
The present double-blind, randomized crossover study
on 12 preschool children with cystic fibrosis, in clinically
stable conditions, shows that the inhalation of HS twice
daily is a safe treatment. To our knowledge, this is the
first study testing Rint technique, an objective measure-
ment of lung function in this range age [10, 12–14], over
a course of HS treatment in children with cystic fibrosis.
Our data, seems to confirm, on a little young population
in the early phase of lung involvement, the short and
middle-term benefits of HS, widely described in litera-
ture on adult patients [1, 2, 7, 15, 16]. In fact, a signifi-
cant improvement of spirometric parameters was
Table 1 Anthropometric characteristics of the participants
Patients
N° 12
Age (years) 5.7 ± 0.8 (range: 4–5.8)
Sex (Males/Females) 5/7
Height (cm) 116 ± 5.7
Weight (Kg) 21.4 ± 3.7
BMI (Kg/m2) 15.9 ± 1.7
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registered after 16-week HS therapy, while a worsening
of those parameters was found in NS group. Similarly,
Rosenfeld et al. have demonstrated a significant im-
provement of FEV0.5 in the group of 7% HS children
younger than 6 years with cystic fibrosis, even if a reduc-
tion of pulmonary exacerbations was not reached [6].
These small changes may reflect a trend of improvement
in airway performance that may result in clinically rele-
vant implications. Subbarao et al. [4] was the pilot study
that analyzed the utility, safety and tolerability of HS
in children. The sole previous study on lung functions
(by spirometry and the raised volume rapid thoracoab-
dominal compression technique) in preschool children
(5.7 ± 0.8 years) with cystic fibrosis who had received
HS therapy was by Dellon et al. [5].
The favorable effect of inhaled HS on airway is carried
out by several postulated molecular mechanisms: HS
breaks ionic bonds within the mucus and shields the
negative charges thereby reducing the viscosity of secre-
tions; it rehydrates airway surface improving mucus rhe-
ology; finally, it induces cough [1, 17, 18]. Moreover, HS
contributes to the improvement of expiratory as well as
inspiratory reduction of airway resistances by reducing
the inflammatory edema of the airway.
In our small series, HS proved to be a safe and tolerable
treatment. The most common adverse event expected
with the introduction of the therapy were cough, throat
irritation and unpleasant salty taste [2]. In our study two
patients referred an increase of cough and one complained
about oropharyngeal irritation. Cough typically decreased
over time. However, we used a premedication with bron-
chodilator to prevent airway bronchoconstriction.
The present study may be of interest also from a
methodological point of view, because it is the first to
utilize the interrupter resistance technique, the gold
standard for this age range, to assess lung function in
preschool children. In fact, measurement of lung func-
tion in young children may be difficult and is prone to
an increased failure rate and increased variability. Con-
ventional lung function tests such as spirometry and
body plethysmography have limited application because
these techniques require a high degree of understanding
and cooperation of the subject [19, 20].
Children in this age group are too old to be sedated
but are unable to actively cooperate in many of the
physiological maneuvers required for the lung function
tests. Probably for this reason, statistically significant re-
sults of FEV1 with the spirometry have not been
obtained.
Rint and spirometry reflect different aspects of the
lung function and are not exactly interchangeable: Rint
is more affected by large airway function and it measures
the total resistance system and some added chest wall
resistance. Moreover, it is a quick, noninvasive measure
Table 2 Lung function measured at time 0 (T0), after 4 (T4) and 16 weeks (T16) in the 12 patients who inhaled hypertonic saline
T0 T4 T16 T0vsT4 T0vsT16
FVC (l) 1.42 ± 0.39 1.45 ± 0.39 1.49 ± 0.42 ns p = 0.02
FVC % pred 89.2 ± 8.3 90.7 ± 7.7 91.9 ± 8.3 p = 0.048 p = 0.02
FEV1 (l) 1.25 ± 0.35 1.16 ± 0.23 1.25 ± 0.38 ns ns
FEV1% pred 87.1 ± 9.5 85.7 ± 8.3 89.6 ± 9.6 ns p = 0.09
FEF25-75 (l/s) 1.43 ± 0.22 1.42 ± 0.36 1.47 ± 0.39 ns ns
FEF25-75% pred 77.0 ± 9.7 74.8 ± 5.6 77.1 ± 5.9 ns ns
Rint exp. kPa(l/s) 1.25 ± 0.19 1.30 ± 0.22 1.24 ± 0.19 ns ns
Rint insp. kPa(l/s) 1.26 ± 0.18 1.28 ± 0.16 1.21 ± 0.20 ns ns
Data were expressed as mean values ± SD
Table 3 Lung function measured at time zero (T0), after 4 (T4) and 16 weeks (T16) in the 12 children who inhaled normal saline
T0 T4 T16 T0vsT4 T0vsT16
FVC (l) 1.31 ± 0.36 1.23 ± 0.28 1.29 ± 0.35 ns ns
FVC % pred. 89.7 ± 8.3 85.4 ± 9.3 87.9 ± 9.1 p = 0.01 ns
FEV1 (1) 1.25 ± 0.25 1.07 ± 0.20 1.14 ± 0.24 p < 0.0001 p < 0.0001
FEV1% pred 90.7 ± 8.6 85.1 ± 7.9 87.8 ± 6.7 p < 0.0001 ns
FEF25-75 (l/s) 1.51 ± 0.39 1.30 ± 0.24 1.40 ± 0.30 p = 0.012 ns
FEF25-75% pred 78.7 ± 6.1 65.9 ± 9.7 72.1 ± 9.4 p = 0.001 p = 0.019
Rint exp. kPa (l/s) 1.23 ± 0.17 1.50 ± 0.33 1.29 ± 0.19 p = 0.02 ns
Rint insp. kPa (l/s) 1.19 ± 0.19 1.37 ± 0.49 1.26 ± 0.21 ns ns
Data were expressed as mean values ± SD
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of respiratory resistance during tidal breathing that may
be more easily performed in the preschooler than spir-
ometry [21, 22]. This technique appeared as a reliable
tool in the diagnostic work-up of pulmonary function in
young CF patients [10, 12–14], even if its use that has
been standardized by the ERS/ATS task force reported
little evidence supporting the clinical utility in the pre-
school population with CF [22]. We consider that Rint
and spirometry could play a role in the evaluation of
pre-school children with CF because they may improve
our ability to detect and treat early lung disease and ex-
acerbations, particularly in pediatric respiratory centers
where other more expensive techniques are not
available.
Nowadays HS therapy may not be considered as an al-
ternative treatment to rhDNase who has demonstrated a
greater ability to improve lung function [3, 23–25] and
to reduce pulmonary complications, but we should al-
ways keep in mind that rhDNase therapy is expensive,
and its use is currently restricted in many countries only
for patients with moderate or severe respiratory effort.
The treatment with hypertonic solution is quite cheap
and safe and permitted at least a short and middle-term
improvement of the respiratory function. The recent
availability of the formulation of HS together with hya-
luronic acid may be helpful in further avoiding the
cough and the burning sensation consequent to the sole
HS [26]. However, in children with CF, to avoid the
potential risk posed by contamination of HS solutions
we should recommend to use sterile unit-dose formu-
lations [27].
Some limitations may be identified in our study, par-
ticularly the small number of the series, the single-
center enrollment and a lack of wash-out period be-
tween the baseline measures.
Moreover, we decided to evaluate CF children in stable
conditions with quite normal spirometric and Rint pa-
rameters at the enrollment. Finally, we limited the lung
function tests to spirometry and Rint, insofar as
multiple-breath inert gas and forced oscillation tech-
nique were not available.
Conclusion
Seven percent hypertonic saline therapy seems to be a
useful and safe treatment in young CF children with
clinically stable conditions. Recently, the CF Foundation
recommends that HS be offered to patients based on in-
dividual circumstances, either for chronic use or during
acute pulmonary exacerbation [28]. Studies on larger
series would be useful to define the effect of this therapy
in particular on spirometric parameters and clinical
outcomes.
Abbreviations
CF: Cystic fibrosis; CFTR: CF transmembrane conductance regulator;
HS: Hypertonic saline; NS: Normal saline; Rint: Interrupter resistance
technique
Acknowledgements
We acknowledge Anna Paola Di Giovambattista for the contribution in
acquisition of data and children and parents for the compliance to the
study.
Funding
None.
Authors’ contributions
RN: analysis performance and interpretation of data for the work and
drafting the work and approved the final manuscript as submitted. CL:
acquisition of the data and approved the final manuscript as submitted.
Fig. 2 Individual changes in in FVC (L), FEV1 (L) and FEF25-75 (L/s) at the baseline (T0), at T4 and T16 for HS (a) and NS (b) groups of children
Nenna et al. Italian Journal of Pediatrics  (2017) 43:60 Page 5 of 6
GDC: acquisition of the data and approved the final manuscript as
submitted. AMZ: acquisition of the data and approved the final manuscript
as submitted. LI: acquisition of the data and approved the final manuscript
as submitted. GC: acquisition of the data and approved the final manuscript
as submitted. PT: acquisition of the data and approved the final manuscript
as submitted. FM: revising the work critically for important intellectual
content and approved the final manuscript as submitted SQ: revising the
work critically for important intellectual content and approved the final
manuscript as submitted. GT: conception and design of the work and
approved the final manuscript as submitted.
Ethics approval and consent to participate
All parents of children gave written informed consent and the protocol
(prot. HS-2009) was approved by the Scientific Ethics Committee, Policlinico
Umberto I.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Pediatrics and Infantile Neuropsychiatry, “Sapienza”
University of Rome, Rome, Italy. 2Cystic Fibrosis Centre-Department of
Pediatrics and Infantile Neuropsychiatry, “Sapienza” University of Rome,
Rome, Italy.
Received: 25 July 2016 Accepted: 7 July 2017
References
1. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, et
al. Effect of increasing doses of hypertonic saline on mucociliary clearance
in patients with cystic fibrosis. Thorax. 1997;52:900–3.
2. Wark P, Mc Donald VM. Nebulised hypertonic saline for cystic fibrosis.
Cochrane Database Sist Rev. 2009;15:CD001506.
3. Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, et al. Effects
of hypertonic saline, alternate day and daily rhDNase on healthcare use,
costs and outcomes in children with cystic fibrosis. Thorax. 2002;57:841–6.
4. Subbarao P, Balkovec S, Solomon M, Ratjen F. Pilot study of safety and
tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr
Pulmonol. 2007;42:471–6.
5. Dellon EP, Donaldson SH, Johnson R, Davis SD. Safety and tolerability of
inhaled hypertonic saline in young children with cystic fibrosis. Pediatr
Pulmonol. 2008;143:1100–6.
6. Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, et al.
Inhaled hypertonic saline in infants and children younger than 6 years with
cystic fibrosis: the ISIS randomized controlled trial. JAMA. 2012;307:2269–77.
7. Reeves EP, Molloy K, Pohl K, McElvaney NG. Hypertonic saline in treatment
of pulmonary disease in cystic fibrosis. ScientificWorldJournal. 2012;2012:
465230.
8. Merkus PJ, Stocks J, Beydon N, Lombardi E, Jones M, McKenzie SA, et al.
Reference ranges for interrupter resistance technique: the asthma UK
initiative. Eur Respir J. 2010;36:157–63.
9. Sly PD, Lombardi E. Measurement of lung function in preschool children
using the interrupter technique. Thorax. 2003;58:742–4.
10. Beydon N, Davis SD, Lombardi E, Allen JL, Arets HG, Aurora P, et al. An
official American Thoracic Society/European respiratory society statement:
pulmonary function testing in preschool children. Am J Respir Crit Care
Med. 2007;175:1304–45.
11. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-
ethnic reference values for spirometry for the 3-95-yr age range: the global
lung function 2012 equations. Eur Respir J. 2012;40:1324–43.
12. Davies PL, Doull IJ, Child F. The interrupter technique to assess airway
responsiveness in children with cystic fibrosis. Pediatr Pulmonol. 2007;42:23–8.
13. Bridge PD, Ranganathan S, McKenzie SA. Measurement of airway resistance
using the interrupter technique in preschool children in the ambulatory
setting. Eur Respir J. 1999;13:792–6.
14. Arets HGM, Brackel HJL, van der Ent CK. Applicability of interrupter
resistance measurements using the MicroRint in daily practice. Respir Med.
2003;97:366–74.
15. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC.
Mucus clearance and lung function in cystic fibrosis with hypertonic saline.
N Engl J Med. 2006;354:241–50.
16. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. A
controlled trial of long-term inhaled hypertonic saline in patients with cystic
fibrosis. N Engl J Med. 2006;354:229–40.
17. King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis
sputum after in vitro treatment with hypertonic saline alone and in
combination with recombinant human deoxyribonuclease. Am J RespirCrit
Care Med. 1997;156:173–7.
18. Willis PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary
transportability of cystic fibrosis and bronchiectasis sputum on the mucus-
depleted bovine trachea. J Clin Invest. 1997;99:9–13.
19. Li AM, Lam HS, So HK, Leung M, Tsen T, Au CT, et al. Interrupter respiratory
resistance in healthy Chinese preschool children. Chest. 2009;136:554–60.
20. Beydon N, Amsallem F, Bellet M. Pulmonary function tests in preschool
children with cystic fibrosis. Am J Respir Crit Care Med. 2002;166:1099–104.
21. Morrison L, Ball R, Conway SP, Brownlee KG. Airway resistance measurements
in children with cystic fibrosis. Physiotherapy. 2003;89:629–36.
22. Rosenfeld M, Allen J, Arets BH, Aurora P, Beydon N, Calogero C, et al. An
official American Thoracic Society workshop report: optimal lung function
tests for monitoring cystic fibrosis, bronchopulmonary dysplasia, and
recurrent wheezing in children less than 6 years of age. Ann Am Thorac
Soc. 2013;10:S1–S11.
23. Flume PA, O'Sullivan BP, Robinsonetal KA. Cystic fibrosis pulmonary
guidelines. Am J of Respir Crit Care Med. 2007;176:957–69.
24. Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med.
2006;354:291–3.
25. Suri R, Metcalfe C, Wallis C, Bush A. Predicting response to rhDNase and
hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol. 2004;37:
305–10.
26. Ros M, Casciaro R, Lucca F, Troiani P, Salonini E, Favilli F, et al. Hyaluronic
acid improves the tolerability of hypertonic saline in the chronic treatment
of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial.
J Aerosol Med Pulm Drug Deliv. 2014;27:133–7.
27. Peled O, Kalamaro V, Kerem E, Shoseyov D, Blau H, Efrati O, Block C.
Contamination of hypertonic saline solutions in use by cystic fibrosis
patients in Israel. J Cyst Fibros. 2014;13:550–6.
28. Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, et al. Clinical
practice guidelines from the cystic fibrosis foundation for preschoolers with
cystic fibrosis. Pediatrics. 2016;137. doi:10.1542/peds.2015-1784.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Nenna et al. Italian Journal of Pediatrics  (2017) 43:60 Page 6 of 6
